(139) designed a unified deep learning architecture based on multimodality sequence messages from CT, laboratory data, and baseline clinical metrics to increase the proportion of NSCLC cases benefiting from anti-PD-1/PD-L1 immunotherapy, thereby fusing multidimensional details to distinguish between cohort anti-PD-1/PD-L1 responders and non-responders. The gene discussed is CD274; the disease is non-small cell lung carcinoma.